Telomerase and cancer: time to move from a promising target to a clinical reality

W N Keith1, T R Jeffry Evans, R M Glasspool

  • 1CRC Department of Medical Oncology, University of Glasgow, CRC Beatson Laboratories, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK. n.keith@beatson.gla.ac.uk

The Journal of Pathology
|December 18, 2001
PubMed

Insights

Cancer cells evade senescence, a key aging process, contributing to uncontrolled growth and immortalization. This review explores senescence bypass, telomerase

Area of Science:

  • Molecular biology of cancer
  • Cellular senescence and immortalization
  • Cancer diagnostics and therapeutics

Background:

  • Significant progress in understanding cancer's molecular underpinnings over the last 25 years.
  • Identification of novel molecular targets for cancer diagnostics and therapies.
  • Four hallmarks of cancer: cell-cycle dysregulation, invasion/metastasis, apoptosis evasion, and senescence bypass.

Purpose of the Study:

  • To review the current understanding of senescence bypass and immortalization in carcinogenesis.
  • To discuss the potential of telomerase in cancer diagnostics.
  • To examine challenges in designing clinical trials for telomerase-based cancer therapies.

Main Methods:

  • Review of existing scientific literature on cancer biology, senescence, and telomerase.
  • Analysis of molecular mechanisms underlying cancer cell hallmarks.
  • Discussion of clinical trial design principles for targeted therapies.

Main Results:

  • Senescence bypass and cellular immortalization are critical processes in cancer development.
  • Telomerase presents realistic opportunities for cancer diagnostics.
  • Significant challenges exist in the clinical application of telomerase therapeutics.

Conclusions:

  • Understanding senescence bypass is crucial for developing new cancer treatments.
  • Telomerase holds promise for cancer detection and therapy, but clinical translation requires careful consideration of trial design.
  • Continued research into cancer's molecular basis will drive innovation in diagnostics and therapeutics.

Related Concept Videos

Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...